



## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington. DC 20231

APPLICATION NO.	FILING DATE	FIRST NAM	ED INVENTOR		ATTORNEY DOCKET NO.	
08/466,921	06/06/95	ALIZON		M	03459.0008-0	
Γ		HM21/0916	٦ [		EXAMINER	
FINNEGAN HENDERSON FARABOW				PARKIN, J		
GARRETT AND	<del> </del>		[	ART UNIT	PAPER NUMBER	
WASHINGTON I		15		1648	1648 2/	
			C	DATE MAILED:	09/16/98	

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 



Application No.

Jeffrey S. Parkin, Ph.D.

Applicant(s)

Advisory Action

08/466,921 Examiner

Group Art Unit

1648

Alizon et al.



т.,	ר פכפו	DD FOR RESPONSE: [check only a) or b)]				
111	a) X	expires 5 months from the mailing date of the final rejection.				
	b) [	expires either three months from the mailing date of the final rejection, or on the mailing date of this Advisory Action, is later. In no event, however, will the statutory period for the response expire later than six months from the date of rejection.	whichever the final			
	date or	ension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate which the response, the petition, and the fee have been filed is the date of the response and also the date for the purring the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be different the originally set shortened statutory period for response or as set forth in b) above.	oses of			
	Appell period	ont's Brief is due two months from the date of the Notice of Appeal filed on (or we for response set forth above, whichever is later). See 37 CFR 1.191(d) and 37 CFR 1.192(a).	rithin any			
Ap but	plicant is NO	s response to the final rejection, filed on $\underline{17  Aug  1998}$ has been considered with the following deemed to place the application in condition for allowance:	effect,			
X	The p	oposed amendment(s):				
	will be entered upon filing of a Notice of Appeal and an Appeal Brief.					
	X w	not be entered because:				
	X	they raise new issues that would require further consideration and/or search. (See note below).				
	X	they raise the issue of new matter. (See note below).				
	X	they are not deemed to place the application in better form for appeal by materially reducing or simplissues for appeal.	fying the			
		they present additional claims without cancelling a corresponding number of finally rejected claims.				
	NO	E: <u>Applicants amendment to the claim language introduces additional limitations (i.e., directed towas stringency hybridization conditions comprising a hybridization reaction involving 20% formamide</u>				
	separ	proposed or amended claims would be allowable if submit te, timely filed amendment cancelling the non-allowable claims.				
		fidavit, exhibit or request for reconsideration has been considered but does NOT place the application bwance because:	in condition			
		fidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were new aminer in the final rejection.	ly raised by			
X	For p	rposes of Appeal, the status of the claims is as follows (see attached written explanation, if any):				
	Claim	allowed: 39-45				
	Claim	objected to:				
	Claim	rejected: 28, 29, and 32-38	ALIDEI DA			
	The p	PONNATHAPURA ACHUTA oposed drawing correction filed on	WURTHY Axaminer.			
	Note	he attached Information Disclosure Statement(s), PTO-1449, Paper No(s)GROUP 1800				
X	Other	at 37 deg. and washing conditions of 2X SSC, 0.1% SDS, at 37 deg.) that would constitute new matter and require further consideration. However, the Examiner has				
	•	rejections. PATENT	PARKIN, PH.D. EXAMINER JIT 1648			

Serial No.: 08/466,921 Applicants: Alizon et al.

5

10

15

25

Docket No.: 3495.0008-09 Filing Date: 06/06/95

## Advisory Action (contd.)

## Suggested Allowable Claim Language

- Claim 32. A purified HIV-1 DNA fragment consisting of a restriction fragment generated by the Bam HI site at approximately 8150 to the Bgl II site at approximately 9150, wherein said numbering scheme is based upon the restriction map of LAV isolate  $\lambda J19$ .
- Claim 33. A purified HIV-1 DNA fragment consisting of a restriction fragment generated by the Bam HI site at approximately 8150 to the Bgl II site at approximately 8750, wherein said numbering scheme is based upon the restriction map of LAV isolate  $\lambda J19$ .
- Claim 34. A purified HIV-1 DNA fragment consisting of a restriction fragment generated by the Kpn I site at approximately 6100 to the Bgl II site at approximately 6500, wherein said numbering scheme is based upon the restriction map of LAV isolate  $\lambda J19$ .
- Claim 35. A purified HIV-1 DNA fragment consisting of a restriction fragment generated by the Kpn I site at approximately 6100 to the Bgl II site at approximately 8750, wherein said numbering scheme is based upon the restriction map of LAV isolate  $\lambda J19$ .
  - Claim 36. A purified HIV-1 DNA fragment consisting of a restriction fragment generated by the *Kpn* I site at approximately 6100 to the *Bgl* II site at approximately 9150, wherein said numbering scheme is based upon the restriction map

Serial No.: 08/466,921 Applicants: Alizon et al.

of LAV isolate  $\lambda J19$ .

5

- Claim 37. A purified HIV-1 DNA fragment consisting of a restriction fragment generated by the  $\mathit{Kpn}$  I site at approximately 3500 to the  $\mathit{Bgl}$  II site at approximately 6100, wherein said numbering scheme is based upon the restriction map of LAV isolate  $\lambda J19$ .
- Claim 38. A purified HIV-1 DNA fragment consisting of a restriction fragment generated by the  $\mathit{Kpn}$  I site at approximately 3900 to the  $\mathit{Kpn}$  I site at approximately 6100, wherein said numbering scheme is based upon the restriction map of LAV isolate  $\lambda$ J19.
- 15 Claims 28 and 29 would be allowable if limited to allowed claims 39-45, or if the aforementioned suggestions are incorporated into claims 32-38.